Grünenthal is a global leader in pain management. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.

... Company

A world free of pain. This is our shared vision. To bring it to life, we execute our strategy and work on our company’s culture – everyday, everywhere, every one of us.

... We are Grünenthal

Grünenthal’s product portfolio, brands, ingredients and indication range.

... Products

A mix of strong entrepreneurial spirit, close collaboration, and outstanding performance define our approach to leadership alongside a commitment to diversity and inclusivity.

... Leadership

The Supervisory Board advises and controls the Corporate Executive Board and is elected by the shareholders’ summit.

... Supervisory Board

We believe compliance, ethics and transparency go hand in hand. Excellence in this area is a key topic for us – and is deeply anchored in our culture.

... Compliance and transparency

Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and innovation is our passion. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.

... Partnering

In view of our vision of a World Free of Pain, Grünenthal strives to provide effective medication to patients worldwide. Therefore, we continuously grow and expand our market presence and product portfolio, and we collaborate with commercial partners and multiple stakeholders from the pain management field and beyond.

... Global presence & sites

Although firmly rooted in Germany, today we are very much a growing global Business.

... History

Being a responsible corporate citizen means operating our business legally, ethically, respectfully and sustainably. All business areas collaborate cross-functionally to manage environmental, social and governance (ESG) risks and make a net-positive impact in our focus areas of Patient, People and Planet.

... Responsibility

At Grünenthal, our vision of a World Free of Pain aligns seamlessly with our commitment to sustainability, especially the social aspect. We regularly evaluate our products, services, and markets to ensure alignment with our sustainability objectives.

... Our responsibility approach

Grünenthal’s focus on patients is at the core of our responsibility approach. We concentrate our efforts on the key areas of patient safety, product quality, improving patients’ quality of life through innovative medicines, access to healthcare and safe pain management through the responsible use of opioids.

... Patient

How can we have a positive impact on the lives of the people we work with, our partners and wider society? Find out what we do to foster trust and promote diversity and inclusion, how we empower our employees to be their best and look after their health and wellbeing, and how we contribute to improving the quality of life for people and communities around us.

... People

We join together with our employees, partners and customers to reduce our carbon footprint, save energy and resources, and decrease waste in our value chain.

... Planet

The Grünenthal Responsible Sourcing Programme will increase transparency and help create a positive ESG impact in our supply chain and connected local communities.

... Responsible sourcing

... Corporate Citizenship

... Thalidomide

Explore our media section and access a range of materials relating to our company.

... Media

Grünenthal is a global leader in pain management and related diseases. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain. Explore our recent stories to see what drives us.

... Our Stories

In this section you will find both current and archived press releases published from 2019 onwards by Grünenthal GmbH, Germany.

... Press releases

... Statements

Journalists are invited to use our corporate publications for their reporting. The list contains business related publication like the company presentation or the code of conduct. .

... Corporate publications

Journalists are invited to use images from our library to illustrate their reporting. The library contains company and R&D related pictures.

... Image resources

The library contains a set of company footage. Journalists are invited to use the video material to illustrate their reporting.

... Video resources

Media - Our stories

Explore our recent stories to see what drives us

06 March 2026

A new era of sustainable API production

Grünenthal API Manufacturing Site Switzerland

At our Mitlödi site, seven interconnected heat pumps now generate all production heat with green electricity, cutting energy use by 38%.

Our API manufacturing site in Mitlödi, Switzerland, has introduced a new way of generating heat to produce active pharmaceutical ingredients (API) by using seven interconnected heat pumps. This innovative system brings us closer to reaching our SBTi (science-based targets initiative)-validated targets and sets a strong foundation for responsible, future-ready manufacturing.

A fresh approach to creating heat in pharma

In January 2026, the site achieved a major milestone: for the first time, all the heat needed for API production was generated using 100% green electricity. This marks a big step forward on our journey towards climate-neutral operations.

How the system works

Seven large industrial heat pumps work together to create the temperatures needed for production, without relying on oil or gas.
When higher temperatures are required, electric boosters provide an additional energy lift.
Heat that would normally be lost – for example, waste heat from condensation processes – is captured and recycled back into the system.

Victor Barbosa, Head of Global Operations and member of the Executive Board Team

“Innovation at Mitlödi shows how we advance sustainable manufacturing with excellence and responsibility.”

Victor Barbosa,

Head of Global Operations at Grünenthal

This innovative approach to the use of electricity, which is rarely seen in the pharmaceutical industry, has led to a 38% decrease in primary energy consumption. With this system now fully operational, our focus shifts to optimising performance, sharing learnings and accelerating the transition to carbon-free energy solutions across our sites.

Strategy, Corporate Responsibility, Sustainability